Inhibition of lymphatic metastases by a survivin dominant-negative mutant

Oncology Research

Volumn 20, Issue 12, 2013, Pages 579-587

  Xu, Guang Chao ^a   Zhang, Peng ^b   Leng, Fei ^a   Pan, Li ^a   Li, Zhi Yong ^a   Yu, Dan Dan ^a   Shan, Yan ^a   Yuan, Qing Zhong ^a   Wen, Yuan ^a   Mu, Bo ^a   Shi, Hua Shan ^a   Chen, Xiang ^a   Wang, Chun Ting ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN CANCER HOSPITAL   (China)

Author keywords

Gene therapy; Lymphangiogenesis; Lymphatic metastasis; Mutation; Survivin

Indexed keywords

SURVIVIN; VASCULOTROPIN D;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SIZE; CAPILLARY DENSITY; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; FEMALE; GENETIC THERAPY; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIPOSOMES; LIVER NEOPLASMS, EXPERIMENTAL; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MICE; MICE, INBRED BALB C; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PLASMIDS; REPRESSOR PROTEINS;

EID: 84887064755     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504013X13775486749416     Document Type: Article

References (33)

1. Chen, X.; Lin, X.; Zhao, J.; Shi, W.; Zhang, H.; Wang, Y.; Kan, B.; Du, L.; Wang, B.; Wei, Y.; et al. A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol. Ther. 16(4): 749-756; 2008. (Pubitemid 351426177)
2. Hou, L.; Tang, J. W.; Cui, X. N.; Wang, B.; Song, B.; Sun, L. Construction and selection of subtracted cDNA library of mouse hepatocarcinoma cell lines with different lymphatic metastasis potential. World J. Gastroenterol. 10(16):2318-2322; 2004. (Pubitemid 39157751)
3. Wen, J.; Fu, A. F.; Chen, L. J.; Xie, X. J.; Yang, G. L.; Chen, X. C.; Wang, Y. S.; Li, J.; Chen, P.; Tang, M. H.; et al. Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model. Int. J. Cancer 124(11): 2709-2718; 2009.
4. Mehlen, P.; Puisieux, A. Metastasis: A question of life or death. Nat. Rev. Cancer 6(6): 449-458; 2006.
5. Wheatley, S. P.; McNeish, I. A. Survivin: A protein with dual roles in mitosis and apoptosis. Int. Rev. Cytol. 247: 35-88; 2005. (Pubitemid 41774364)
6. Chakravarti, A.; Noll, E.; Black, P. M.; Finkelstein, D. F.; Finkelstein, D. M.; Dyson, N. J.; Loeffler, J. S. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J. Clin. Oncol 20(4): 1063-1068; 2002. (Pubitemid 34141851)
7. Shinohara, E. T.; Gonzalez, A.; Massion, P. P.; Chen, H.; Li, M.; Freyer, A. S.; Olson, S. J.; Andersen, J. J.; Shyr, Y.; Carbone, D. P.; et al. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer 103(8): 1685-1692; 2005. (Pubitemid 40490030)
8. Tran, J.; Master, Z.; Yu, J. L.; Rak, J.; Dumont, D. J.; Kerbel, R. S. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl. Acad. Sci. USA 99(7): 4349-4354; 2002. (Pubitemid 34285988)
9. Chakravarti, A.; Zhai, G. G.; Zhang, M.; Malhotra, R.; Latham, D. E.; Delaney, M. A.; Robe, P.; Nestler, U.; Song, Q.; Loeffler, J. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 23(45): 7494-7506; 2004. (Pubitemid 39389691)
10. Wall, N. R.; O'Connor, D. S.; Plescia, J.; Pommier, Y.; Altieri, D. C. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res. 63(1): 230-235; 2003. (Pubitemid 36070444)
11. Peng, X. C.; Yang, L.; Yang, L. P.; Mao, Y. Q.; Yang, H. S.; Liu, J. Y.; Zhang, D. M.; Chen, L. J.; Wei, Y. Q. Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34→Ala mutant. J. Exp. Clin. Cancer Res. 27:46; 2008.
12. Ichiki, Y.; Hanagiri, T.; Takenoyama, M.; Baba, T.; Fukuyama, T.; Nagata, Y.; Mizukami, M.; So, T.; Sugaya, M.; Yasuda, M.; et al. Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy. Lung Cancer 48(2): 281-289; 2005.
13. Chen, T.; Deng, C. Inhibitory effect of siRNA targeting survivin in gastric cancer MGC-803 cells. Intl. Immunopharmacol. 8(7): 1006-1011; 2008.
14. Rodel, F.; Frey, B.; Leitmann, W.; Capalbo, G.; Weiss, C.; Rodel, C. Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int. J. Rad. Oncol. Biol. Phys. 71(1): 247-255; 2008. (Pubitemid 351491424)
15. Altieri, D. C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 3(1): 46-54; 2003. (Pubitemid 37328886)
16. Mesri, M.; Wall, N. R.; Li, J.; Kim, R. W.; Altieri, D. C. Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Invest. 108(7): 981-990; 2001. (Pubitemid 32946072)
17. Le Voyer, T. E.; Sigurdson, E. R.; Hanlon, A. L.; Mayer, R. J.; Macdonald, J. S.; Catalano, P. J.; Haller, D. G. Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J. Clin. Oncol. 21(15): 2912-2919; 2003. (Pubitemid 46621841)
18. Kim, M. J.; Lim, K. Y.; Kim, J. W.; Nam, I. W.; Lee, J. H.; Myoung, H. Stage and mRNA expression of survivin in lymph node as prognostic indicators in patients with oral squamous cell carcinoma. Cancer Lett. 224(2): 253-261; 2005. (Pubitemid 40725846)
19. Templeton, N. S.; Lasic, D. D.; Frederik, P. M.; Strey, H. H.; Roberts, D. D.; Pavlakis, G. N. Improved DNA: Liposome complexes for increased systemic delivery and gene expression. Nat. Biotechnol. 15(7): 647-652; 1997. (Pubitemid 27291165)
20. Lin, X.; Chen, X.; Wei, Y.; Zhao, J.; Fan, L.; Wen, Y.; Wu, H.; Zhao, X. Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice. Gynecol. Oncol. 104(3): 540-546; 2007. (Pubitemid 46240242)
21. Cui, X. N.; Tang, J. W.; Hou, L.; Song, B.; Li, L.; Liu, J. W. Screening differentially expressed genes in mouse hepatocarcinoma ascites cell line with high potential of lymphatic metastasis. World J. Gastroenterol. 11(12): 1837-1842; 2005. (Pubitemid 40520781)
22. Deguchi, M.; Shiraki, K.; Inoue, H.; Okano, H.; Ito, T.; Yamanaka, T.; Sugimoto, K.; Sakai, T.; Ohmori, S.; Murata, K.; et al. Expression of survivin during liver regeneration. Biochem. Biophys. Res. Commun. 297(1): 59-64; 2002.
23. Achen, M. G.; Stacker, S. A. Molecular control of lymphatic metastasis. Ann. NY Acad. Sci. 1131: 225-234; 2008. (Pubitemid 351758517)
24. Cheung, C. H.; Chen, H. H.; Kuo, C. C.; Chang, C. Y.; Coumar, M. S.; Hsieh, H. P.; Chang, J. Y. Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Mol. Cancer 8:43; 2009.
25. Christiansen, A.; Detmar, M. Lymphangiogenesis and cancer. Genes Cancer 2(12): 1146-1158; 2011.
26. Ryan, B. M.; Konecny, G. E.; Kahlert, S.; Wang, H. J.; Untch, M.; Meng, G.; Pegram, M. D.; Podratz, K. C.; Crown, J.; Slamon, D. J.; et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann. Oncol. 17(4): 597-604; 2006.
27. Lohela, M.; Bry, M.; Tammela, T.; Alitalo, K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr. Opin. Cell Biol. 21(2): 154-165; 2009.
28. Brundler, M. A.; Harrison, J. A.; de Saussure, B.; de Perrot, M.; Pepper, M. S. Lymphatic vessel density in the neoplastic progression of Barrett's oesophagus to adenocarcinoma. J. Clini. Pathol. 59(2): 191-195; 2006. (Pubitemid 43235586)
29. Wirzenius, M.; Tammela, T.; Uutela, M.; He, Y.; Odorisio, T.; Zambruno, G.; Nagy, J. A.; Dvorak, H. F.; Yla-Herttuala, S.; Shibuya, M.; et al. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J. Exp. Med. 204(6): 1431-1440; 2007. (Pubitemid 46919880)
30. Karpanen, T.; Alitalo, K. VEGF-D: A modifier of embryonic lymphangiogenesis. Blood 112(5): 1547-1548; 2008.
31. Karnezis, T.; Shayan, R.; Caesar, C.; Roufail, S.; Harris, N. C.; Ardipradja, K.; Zhang, Y. F.; Williams, S. P.; Farnsworth, R. H.; Chai, M. G.; et al. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell 21(2): 181-195; 2012.
32. Hirakawa, S.; Kodama, S.; Kunstfeld, R.; Kajiya, K.; Brown, L. F.; Detmar, M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J. Exp. Med. 201(7): 1089-1099; 2005. (Pubitemid 40524677)
33. Albrecht, I.; Christofori, G. Molecular mechanisms of lymphangiogenesis in development and cancer. Int. J. Dev. Biol. 55(4-5): 483-494; 2011.